Skye Bioscience’s obesity drug nimacimab, a peripherally restricted CB1 receptor inhibitor antibody, failed to meet the primary endpoint in a 26-week Phase 2a trial as monotherapy, resulting in a 60% plunge in shares. Despite this setback, combination treatment with semaglutide demonstrated clinically meaningful additional weight loss. The company plans to explore higher dosing and further trials. This outcome highlights the challenges in advancing cannabinoid receptor-targeting therapies for obesity.